Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Core One Labs (COOL) announced the company is pursuing a listing on the Capital Market tier of The Nasdaq Stock Market LLC
  • The company believes the Nasdaq listing would enhance its investor profile and increase value for shareholders
  • As of July 15, the company’s common shares began trading on the Canadian Securities Exchange on an 8:1 post-consolidation basis
  • The consolidation represents a significant step towards the listing of the Company on Nasdaq
  • Core One Labs is up 1.12 per cent, trading at C$4.50 at 11:07 am ET

Core One Labs (COOL) announced the company is pursuing a listing on the Capital Market tier of The Nasdaq Stock Market LLC.

The Vancouver biotech company believes the Nasdaq listing would enhance its investor profile and increase value for shareholders.
The listing would also allow the company to further US business development, both in terms of attracting institutional and retail investors, as well as through possible merger and acquisition opportunities.
Any merger or acquisition opportunities would complement the company’s existing business divisions, with a focus on the advancement of the safe medical use of psychedelics for the treatment of mental health and neurological disorders.
As of July 15, the company’s common shares began trading on the Canadian Securities Exchange on an 8:1 post-consolidation basis. The consolidation represents a significant step towards the listing of the company on the Nasdaq. The company will continue to take steps to fulfil the other requirements set by Nasdaq for a successful listing application.
“The company’s decision to proceed with this share consolidation is a significant step forward for Core One and illustrates the Company’s commitment to advancing its Nasdaq listing application. Our goals as a Company is to increase shareholder value, enhance exposure in international markets, and to become a leader in the psychedelics space. Our pursuit of a Nasdaq listing is another step towards fulfilling these goals,” said Core One CEO Joel Shacker.
Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. 
Core One Labs is up 1.12 per cent, trading at C$4.50 at 11:07 am ET.
More From The Market Herald

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.

" Clearmind Medicine (CSE:MIND) and SciSparc report positive results for Psychedelic Combination Treatment

Clearmind Medicine (MND) has released favourable safety profile results from its joint pre-clinical trial with SciSparc Ltd. (NASDAQ: SPRC).

" Optimi Health (CSE:OPTI) acquires catalog of psychedelic and functional mushroom genetics

Optimi Health (OPTI) has acquired a catalog of psilocybin and functional mushroom strains.

" Nirvana Life Sciences Inc (CSE:NIRV) signs LOI with Innovate Phytotechnologies Inc

Nirvana Life Sciences (NIRV) has  signed a letter of intent with Innovate Phytotechnologies Inc. (INVP)